UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 29, 2024 Or STAAR Surgical Company (Exact Name of Registrant as Specified in its Charter) (State or Other Jurisdiction of Incorporation or Organization) 25651 Atlantic Ocean Drive Lake Forest, California 92630 (Address of Principal Executive Of ices) (Zip Code) Delaware 95-3797439 (I.R.S. E ...

Exhibit 99.1 STAAR Surgical Reports First Quarter 2024 Results EVO ICL™ Continues to Outpace Refractive Industry Growth Record Quarterly U.S. Sales and Multiple Strategic Agreements Secured Reiterates Fiscal 2024 Net Sales Outlook and Increases Adjusted EBITDA LAKE FOREST, CA, May 7, 2024 --- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today reported financial result ...

Financial Performance - For the fiscal year ended December 29, 2023, STAAR Surgical Company reported worldwide revenue of $322.4 million, with 99% generated from sales of implantable Collamer lenses (ICLs) [229]. - Net sales for 2023 increased by 13% from 2022, driven by an increase in ICL sales of $49.7 million, despite a decrease in other product sales of $11.7 million [233]. - Total ICL sales for 2023 increased by 18% from 2022, with unit growth of 19%, primarily driven by the APAC region, which grew by 21% [235]. - Gross profit for 2023 was $252.7 million, representing a 13.1% increase from 2022, while the gross profit margin slightly decreased to 78.4% [240]. - Other income (expense), net for 2023 was $5,599,000, a significant increase from $1,750,000 in 2022, primarily due to increased interest income [249]. - Provision for income taxes in 2023 was $12,349,000, up from $5,887,000 in 2022, with an effective tax rate of 36.6% [252]. Expenses - General and administrative expenses for 2023 increased by 32.1% from 2022, totaling $72.3 million, primarily due to increased salary-related expenses and one-time employee benefits in Japan [242]. - Selling and marketing expenses for 2023 increased by 21.4% to $107,834,000 from $88,856,000 in 2022, representing 33.4% of sales [244]. - Research and development expenses for 2023 rose by 23.4% to $44,401,000 from $35,983,000 in 2022, accounting for 13.8% of sales [246]. Cash Flow and Assets - Cash and cash equivalents increased to $183,038,000 in 2023 from $86,480,000 in 2022, while total current assets rose to $365,269,000 [255]. - Net cash provided by operating activities in 2023 was $14,594,000, down from $35,715,000 in 2022 [258]. - Accounts receivable, net increased to $94,700,000 in 2023 from $62,400,000 in 2022, with Days' Sales Outstanding (DSO) rising to 113 days [261]. - Inventories, net rose to $35,100,000 in 2023 from $24,200,000 in 2022, with Days' Inventory on Hand (DOH) increasing to 142 days [262]. Strategic Plans - The company plans to increase strategic collaborations with leading refractive surgeons in the U.S. and invest in enhanced systems for faster ordering and fulfillment in 2024 [230]. - STAAR Surgical Company intends to focus on product innovation, particularly new lens delivery devices and next-generation lens technologies in 2024 [230]. - The company plans to continue investing in new products and expanding its market presence, supported by its current liquidity and capital resources [254]. Market and Currency Risks - Approximately 95% of total sales during 2023 were generated from activities outside the U.S., exposing the company to foreign currency exchange risks [274]. - The strengthening of the U.S. dollar negatively affected consolidated sales and gross profit, particularly impacting sales in China, which accounted for 58% of consolidated net sales during fiscal 2023 [275]. - The company does not actively hedge against currency rate fluctuations, which may lead to transaction gains or losses reported in total other income [274]. - The company does not currently hedge transactions to offset changes in foreign currency, relying on management's judgment regarding risks and opportunities [273]. Inventory and Taxation - The company provides allowances for sales returns based on an expected loss model, considering historical returns and current trends [265]. - Stock-based compensation expense is measured using the Black-Scholes pricing model, with adjustments made based on performance conditions and probability assessments [266]. - The company evaluates deferred tax assets based on historical results and projected future taxable income, considering various tax-planning strategies [267]. - Estimated inventory allowances are provided for excess and obsolete inventory, with regular reviews based on market conditions and product demand forecasts [268]. - Management believes inflation has not significantly impacted net sales and revenues over the past three years [271]. - The company regularly reassesses the adequacy of inventory provisions based on demand forecasts and market conditions [268].

STAAR Surgical Company (NASDAQ:STAA) Q4 2023 Earnings Conference Call February 26, 2024 4:15 PM ET Company Participants Brian Moore - Vice President-Investor Relations & Corporate Development Tom Frinzi - President & Chief Executive Officer Patrick Williams - Chief Financial Officer. Conference Call Participants Patrick Wood - Morgan Stanley John Young - Canaccord Margaret Andrew - William Blair George Sellers - Stephens Inc. Ryan Zimmerman - BTIG Anthony Petrone - Mizuho Group Matthew O'Brien - Piper Sandl ...

Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 29, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-11634 UNITED STATES SECURITIES AND EXCHANGE COMMISSION STAAR Surgical Company (Exact Name of Registrant as Specified in its Charter) (State or Other Jurisdiction of Incorporation or Organization) 25651 Atlan ...

STAAR Surgical Company (NASDAQ:STAA) Q3 2023 Earnings Conference Call November 1, 2023 4:30 PM ET Company Participants Brian Moore - Vice President-Investor Relations & Corporate Development Tom Frinzi - President & Chief Executive Officer Patrick Williams - Chief Financial Officer. Conference Call Participants Anthony Petrone - Mizuho Xuyang Li - Jefferies John Young - Canaccord George Sellers - Stephens Margaret Kaczor Andrew - William Blair Steve Lichtman - Oppenheimer Operator Good day ladies and gentle ...

Financial Data and Key Metrics Changes - Total net sales for Q2 2023 were $92.3 million, up 14% compared to $81.1 million in Q2 2022 and up 26% sequentially from Q1 2023 [7] - Gross profit for Q2 2023 was $70.7 million, or 76.6% of net sales, compared to $63.9 million, or 78.8% of net sales in Q2 2022 [93] - Operating income in Q2 2023 was $8.6 million, or 9.3% of net sales, down from $17 million, or 21% of net sales in Q2 2022 [95] Business Line Data and Key Metrics Changes - ICL sales increased by $50 million, or 19%, year-over-year, while other product sales decreased by $4 million [7] - ICL sales for Q2 2023 were $93.1 million, with global ICL sales growth of 19% and unit growth of 21% [117] - Research and development expense was $11.8 million in Q2 2023, up from $8.6 million in Q2 2022 [9] Market Data and Key Metrics Changes - Sales in the EMEA region declined by 9% due to macroeconomic and geopolitical factors, but ICL units in European markets increased by 6% [4] - APAC region saw a 29% increase in ICL units and a 26% increase in sales for Q2 2023 [117] - The U.S. refractive market experienced a 15% year-over-year decline, while STAAR's ICL sales grew by 10% [91][67] Company Strategy and Development Direction - The company aims to remain a high-growth organization, targeting 20% annual growth, particularly in APAC and the U.S. [6][16] - New analytic tools are being implemented to better target high-volume customers and improve marketing effectiveness [5] - A patient call center education and surgeon referral program is being piloted to enhance patient engagement and conversion [5] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the U.S. market despite current challenges, emphasizing the need for time to transition EVO from a niche to a mainstream procedure [13] - The company anticipates a strong performance in China, with a positive start to the peak season for ICLs [16][61] - Management acknowledged the need for adjustments in digital marketing strategies due to lower-than-expected returns [122] Other Important Information - The company expects to invest approximately $26 million in property and equipment for the year, primarily for manufacturing capacity expansion [10] - The effective tax rate is expected to be approximately 35% in Q3 and Q4 due to reduced profitability in the U.S. [123] Q&A Session Summary Question: What is the outlook for the U.S. market? - Management indicated that the U.S. market is expected to remain flat in the second half of the year, with plans to enhance training and education efforts to drive growth in 2024 [104][132] Question: How is the company addressing the challenges in digital marketing? - The company is reducing digital marketing investments until they can ensure better patient conversion rates and cost-effectiveness [122] Question: What is the confidence level regarding growth in China? - Management expressed high confidence in the Chinese market, noting strong surgeon support and positive sales activity [61][68]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-11634 STAAR Surgical Company (Exact Name of Registrant as Specified in its Charter) Delaware 95-3797439 (State or Other Jurisdiction of (I.R.S. Employer Incorporat ...

STAAR Surgical Company (NASDAQ:STAA) Q1 2023 Earnings Conference Call May 3, 2023 4:30 PM ET Company Participants Brian Moore - VP of Investor, Media Relations and Corporate Development Tom Frinzi - President and CEO Patrick Williams - CFO Conference Call Participants Anthony Petrone - Mizuho Group Margaret Kaczor - William Blair Samuel Durno - BTIG John Young - Canaccord Yang Li - Jefferies David Saxon - Needham Ron Feiner - Oppenheimer Harrison Parsons - Stephens Inc. Tom Stephan - Stifel Jim Sidoti - Sid ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-11634 (State or Other Jurisdiction of Incorporation or Organization) 25651 Atlantic Ocean Drive Lake Forest, California 92630 (Address of Principal Executive Of i ...